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Summary
We conducted a population-based study to determine
the contribution of germline mutations in known can-
didate genes to ovarian cancer diagnosed at age !30
years. Women with epithelial ovarian cancer were iden-
tified through cancer registries. DNA samples were an-
alyzed for mutations in BRCA1, the “ovarian can-
cer–cluster region” (nucleotides 3139–7069) of BRCA2,
and the mismatch-repair genes hMSH2 and hMLH1.
Probable germline mutations in hMLH1 were identified
in 2 (2%; 95% confidence interval 1%–8%) of 101
women with invasive ovarian cancer diagnosed at age
!30 years. No germline mutations were identified in any
of the other genes analyzed. There were no striking ped-
igrees suggestive of families with either breast/ovarian
cancer or hereditary nonpolyposis colorectal cancer
(HNPCC). There was a significantly increased incidence
of all cancers in first-degree relatives of women with
invasive disease (relative risk [RR] = 1.6, ) butP = .01
not in second-degree relatives or in relatives of women
with borderline cases. First-degree relatives of women
with invasive disease had increased risks of ovarian can-
cer (RR = 4.8, ), myeloma (RR = 10, ),P = .03 P = .01
and non-Hodgkin lymphoma (RR = 7, ). Germ-P = .004
line mutations in BRCA1, BRCA2, msh2, andmlh1 con-
tribute to only a minority of cases of early-onset epi-
thelial ovarian cancer. Our data suggest that early-onset
ovarian cancer is not associated with a greatly increased
risk of cancer in close relatives.
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Introduction
Inherited mutations of BRCA1 (MIM 113705),
BRCA2 (MIM 600185), and the mismatch-repair genes
are known to confer predisposition to ovarian cancer
(Ford and Easton 1995). Of these genes, BRCA1 is
thought to be responsible for the disease in the majority
of families with breast/ovarian and site-specific ovarian
cancer (Narod et al. 1995). Approximately 5% of ovar-
ian cancers diagnosed at age !70 years are due to germ-
line mutations of BRCA1 (Stratton et al. 1997). Early
age at onset of cancer is often regarded as an indicator
of underlying inherited predisposition to cancer, most
notably for breast and large-bowel cancer. Of breast
cancers diagnosed in women of age !30 years, 15%
arise as a result of inherited mutations in BRCA1 (Fitz-
gerald et al. 1996; Langston et al. 1996; Krainer et al.
1997). Whittemore et al. (1997), using data from three
U.S. population-based case-control studies, estimated
that 18% of epithelial ovarian cancers occurring at age
130 years were due to germline BRCA1 mutations,
whereas Ford et al. (1995) derived a more conservative
estimate, 6%, from population-based British data. Per-
haps it is somewhat surprising, therefore, that only one
study has reported epithelial ovarian cancer that de-
veloped at age !30 years in a BRCA1-mutation carrier
(Rubin et al. 1996). The scarcity of reports of early-
onset epithelial ovarian cancer in women with BRCA1
mutations may be the result of ascertainment bias to-
ward early-onset breast cancer, in the ascertainment of
families for genetic study. To determine the contribu-
tion of known ovarian-cancer–predisposing genes to
early-onset ovarian cancer, we set up a retrospective
population-based study for the identification of all
cases of early-onset epithelial ovarian cancer during a
10-year period. We collected information on cancer in-
cidence among first- and second-degree relatives, to de-
termine whether their relatives were at increased risk
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of cancer and whether there was evidence of a partic-
ular pattern of cancers among family members.
Methods
Study Design
Women of age !30 years who had epithelial ovarian
cancer diagnosed in 1984–93 were eligible to enter the
study. Women with borderline tumors were included.
Patients’ names and their consultants’ (hospital special-
ists) names were obtained from the following United
Kingdom cancer registries: East Anglian, Thames, Trent,
Wessex, Oxford, South Western, West Midlands, Mersey
and Cheshire, Wales, West of Scotland, Scottish, and
Northern Ireland. We wrote to the patients’ consultants
to obtain their permission to contact their patients, if
the patients were still alive, and to provide us with the
names and addresses of the patients’ general practition-
ers (GPs). For patients who had died, we asked their
consultants to provide us with details of their histolog-
ical type of cancer, clinical staging, type of surgery un-
dertaken, adjuvant therapy, and duration of follow-up.
We also requested pathology reports and pathology ma-
terial from these individuals. For patients who were
alive, we wrote to their GPs to obtain their permission
to contact their patients and, also, to request their help
in obtaining a blood sample. When we received per-
mission from the patients’ GPs, we contacted the patients
by letter, telling them about the study and asking
whether they would be willing to participate. Patients
who agreed to enter the study were asked to complete
a questionnaire giving details of their medical history,
including parity and oral contraceptive use. Participants
were also asked to complete a table giving the names,
dates of birth, vital status, and dates of death of all their
first- and second-degree relatives and to indicate which
individuals had cancer develop, including type of cancer
and age at diagnosis. We requested that one 20-ml blood
sample be obtained from each patient; this was taken
either by the patient’s GP or by a practice nurse and was
collected in two 10-ml containers that we provided. If
either the patient or the GP was unwilling for a blood
sample to be drawn, a mouth swab was requested in-
stead. The patients’ consultants were sent the same ques-
tionnaire described previously for patients who had died.
We also requested pathology reports and pathology ma-
terial. All nonresponders (consultants, GPs, and pa-
tients) to any of the letters were sent a single reminder.
We attempted to trace lost patients and GPs through the
National Health Service Central Registry and the Family
Health Services Authorities.
Ethics
One hundred five ethics committees located through-
out the United Kingdom and Northern Ireland districts
covered by the cancer registries, as well as the British
Medical Association Central Ethical Committee, ap-
proved the study protocol. Ethical approvals were ob-
tained by collaborators in their regions. Written, wit-
nessed consent was obtained from all participating wo-
men. Participants were also asked to indicate whether
they wished to be informed of the results of the mu-
tation analysis.
Statistics
Comparison of the observed and expected incidence
of cancers in first- and second-degree relatives was per-
formed by use of the PERSON-YEARS program, version
1.21 (Coleman et al. 1989). Expected numbers of can-
cers were calculated from age-, sex-, and period-specific
incidence rates for England and Wales (Electronic Da-
tabase of Cancer Incidence in Five Continents).
For each relative, the date of entry into the cohort
was defined as either the date of birth (estimated where
unknown) or January 1955, whichever came later. The
date of exit was either the date of cancer diagnosis or,
if there was no cancer, either the date of death or the
date last seen, as appropriate. For living relatives, date
last seen was assumed to be January 1, 1997, whereas
deceased relatives without a date of death were given
a date on the basis of their relationship to the index
case—for example, deceased grandparents without re-
ported illnesses were assumed to have lived 75 years
from their date of birth. Relatives whose dates of birth
were unknown were assigned dates of birth on the basis
of their relationship to the index case—for example,
grandparents were assigned a date of birth 25 years
before the date of birth of the relevant parent of the
index case. Relatives born before 1890 and relatives
who had died or who had developed cancer before
1955 were excluded from the analysis. The analysis was
performed twice—once with individuals being censored
on their 85th birthday and once with the earlier cen-
soring age, 60 years. Analyses were performed sepa-
rately for the relatives of index cases with invasive can-
cer and the relatives of index cases with borderline
tumors. Significance levels were calculated on the basis
of both the Poisson assumption and age.
Pathology
Ten 5-mm sections were cut from all paraffin-wax
tumor blocks received and were mounted on glass
slides. One slide was hematoxylin-eosin–stained and
was reviewed by one of two reference pathologists, in
Stratton et al.: Genetics of Ovarian Cancer in Women of Age !30 Years 1727
conjunction with the histology report, where avail-
able.
Mutation Analysis
Genomic DNA was extracted from blood or from
mouth swabs, by standard methods, by an Extragen au-
tomated DNA extractor.
BRCA1.—Twenty-eight primer pairs were used to
amplify the entire BRCA1 coding sequence and intron-
exon boundaries for screening by multiplex hetero-
duplex analysis. DNA fragments were subsequently
electrophoresed through 20-cm#20-cm#.1-cm, non-
denaturing 1#MDE gels (Flowgen), by use of the Pro-
tean IITM vertical-slab-gel apparatus (Bio-Rad). Elec-
trophoresis was performed for 12 h at a constant 250
V, with gels cooled to 10C. All gels were stained with
silver nitrate, according to standard procedures (Gay-
ther et al. 1995, 1996; Glavac and Dean 1995; Rossetti
et al. 1995).
BRCA2.—BRCA2 was screened for mutations in the
ovarian cancer–cluster region (nucleotides 3139–7069),
by means of the protein-truncation test (PTT). PTT was
performed with the TNTT rabbit reticulocyte-lysate sys-
tem (Promega), incorporating [35S] methionine for pro-
tein detection (Foster et al. 1996; Friedman et al. 1997;
Gayther et al. 1997).
hMSH2 and hMLH1.—The entire coding regions of
both these genes were amplified and were screened by
combined single-stranded conformation and heterodu-
plex analysis (SSCA/HA) on 0.6#MDE gels (Flowgen),
by use of the Protean IITM vertical-slab-gel apparatus
(Bio-Rad). Electrophoresis was performed for 12 h at a
constant 150–170 V, with gels cooled to 10C. All gels
were stained with silver nitrate, according to standard
procedures (Glavac and Dean 1993; Borresen et al.
1995; Han et al. 1995, 1996; Moslein et al. 1996). All
variants were characterized by DNA cycle sequencing,
with the use of AmpliTaq-FS DNA polymerase (Applied
Biosystems) on an Applied Biosystems 373A automated
sequencer.
Results
For the purposes of this study, we identified 663
women through the cancer registries. Of these women,
140 were known to be dead and 7 were untraceable.
Of the 516 women still possibly alive, we did not re-
ceive, from their hospital specialist, permission to pro-
ceed in 43 cases, and we were unable to identify the
patient’s current GP in 36 cases. A further 38 GPs did
not respond to our letter, and 27 refused permission to
contact their patients. A further 59 GPs who replied
were unable to give permission to proceed with the
study, since they had lost contact with their patients.
This left 313 women who were contacted to take part
in the study. Two women were subsequently excluded
when pathology review revealed them to have germ-
cell tumors. Of these 311 women, clinical details were
obtained for 198, family-history information for 172,
blood samples for 191, mouth swabs for 5, and archival
pathology material for 121. Age range at diagnosis in
the 198 women was 13–29 years, with a median of 25
years. Of the 140 women known to have died, clinical
details for 96 were obtained through their consultant,
and pathological material was obtained for 60. The age
range at diagnosis in this group was 11–29 years, with
a median of 25 years.
Family History
Results of the PERSON-YEARS analysis are pre-
sented in table 1. Results for borderline and invasive
tumors are shown separately, since it is unclear whether
they are part of the same disease process. Because of
the greater likelihood of cancer sites being misreported
among second-degree relatives and because familial ef-
fects are likely to be stronger among first-degree rela-
tives, we analyzed the familial risks in first- and second-
degree relatives separately. The lack of excess of cancers
overall, in either first- or second-degree relatives of
women with invasive and borderline tumors taken to-
gether, suggests that there is no significant recall bias.
First-degree relatives of women with invasive ovarian
cancer had a marginally increased risk of cancer overall
(30 vs. 19, RR = 1.6, (table 1). They had aP = .01
significantly increased risk of ovarian cancer (RR = 4.8,
) if followed to age 85 years, but this was notP = .03
significant in the smaller subset of relatives of age !60
years. Although slightly more cases of breast cancer were
observed than were expected, the difference was not sig-
nificant. There was, however, an excess of non-Hodgkin
lymphoma (4 vs. 0.6, RR = 7, ) and multipleP = .004
myeloma (2 vs. 0.2, RR = 10, ).P = .01
Among second-degree relatives of women with inva-
sive cancer, there was a greater-than-expected incidence
of both lung cancer (26 vs. 16, RR = 1.6, ) andP = .01
liver cancer at age !60 years (2 vs. 0.1, RR = 20, P =
); however, these findings cannot be interpreted with.01
confidence, since a report of “lung cancer” or “liver
cancer” unconfirmed by medical evidence may reflect
metastatic disease. First-degree relatives of women with
borderline cancers had increased risks of prostate cancer
(3 vs. 0.3, RR = 10, ) and Hodgkin lymphomaP = .002
(2 vs. 0.2, RR = 10, ), which were not presentP = .02
in relatives of women with invasive cancer. Second-de-
gree relatives of women with borderline tumors had in-
creased risks of both cancer of the larynx (3 vs. 0.6, RR
= 5, ) and ovarian cancer at age !60 years (4 vs.P = .02
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Table 1
Cancer Incidence in First- and Second-Degree Male and Female Relatives of Index Cases with
Ovarian Cancer at Age !30 Years
NO. OF EXPECTED CASES/NO. OF OBSERVED CASES
Invasive Tumor Borderline Tumor
CANCER TYPE IN INDEX CASE
First-Degree
Relatives
Second-Degree
Relatives
First-Degree
Relatives
Second-Degree
Relatives
Breast 5/3.5 12/11 2/2.2 11/8.6
Ovary 3*/.6 3/2.3 1/.4 4***/1.7
Pharynx 0/.4 1/.6 0/.2 1/1
Esophagus 1/.4 0/1.7 0/.2 0/1
Stomach 1/.8 8/5 1/.4 4/3
Colon 2/1.2 10***/6 0/.6 4/3.7
Rectum 1/.8 0/4 1/.4 0/2.5
Liver 0/.1 2***/.4 0/.05 0/.3
Pancreas 2***/.4 1/2.3 1/.2 0/1.4
Larynx 0/.2 2/.9 0/.1 3*/.6
Lung 1/2.9 26*/16 1/1.4 5/8.9
Bone 0/.09 0/.2 0/.06 0/.1
Connective tissue 0/.15 0/.4 0/.09 0/.3
Melanoma 0/.5 1/1.1 0/.3 0/.8
Cervix 2/.8 3/2.1 1/.5 0/1.7
Uterus 0/.4 1/2 0/.3 4***/1.4
Prostate 2/.6 4/4 3**/.3 0/2
Testis 0/.3 0/.4 0/.2 1/.3
Bladder 1/.9 0/4 0/.4 1/2.4
Kidney 0/.4 1/1.5 0/.2 0/1
Brain 0/.6 3/1.7 0/.4 1/1.2
Thyroid 1/.1 0/.3 0/.08 0/.2
Hodgkin 0/.3 1/.6 2*/.2 0/.4
Non-Hodgkin lymphoma 4**/.6 0/1.9 1/.4 0/1.2
Myeloma 2*/.2 0/.9 0/.1 0/.5
Leukemia 0/.6 0/1.7 0/.3 0/1.1
Other cancers 0/.4 0/1.6 0/.2 0/1
Unknown 0/.8 1/4 0/.4 0/2.5
All except nonmelanoma skin 30*/19 80/82 14/11 39/51
All except skin, breast, and ovary 22***/15 65/68 11/8 24/41
NOTE.—Number of male and female relatives at risk is 1,968.
* .P ! .05
** .P ! .01
*** .P ! .1
1, RR = 3.8, ), but they had no increased risk ofP = .02
cancer overall.
The possibility that some of these women with early-
onset ovarian cancer might be members of families with
a presumed breast/ovarian cancer syndrome was of ob-
vious interest, as was the question of the risk of ovarian
cancer at a young age in their siblings and the risk of
second primary cancers in the patients themselves. There
were no pedigrees with striking aggregates of early-onset
cases. One family had a paternal aunt with bilateral
breast cancer, at age 35 and at 45 years; there were no
families with both a further case of ovarian cancer at
any age and a further case of breast cancer at age !50
in close relatives. No woman had more than one relative
with ovarian cancer; of the 13 cases of ovarian cancer
reported in relatives, 4 were in first-degree relatives (at
ages 28, 41, 66, and 72 years). The age range at diag-
nosis of the nine ovarian cancers in second-degree rel-
atives was 28–65 years. Five patients were reported to
have second primary cancers; one had an endometrioid
adenocarcinoma of the ovary at age 25 years and a tran-
sitional-cell cancer of the bladder 8 mo later (both tu-
mors were confirmed by histology), and one had a con-
firmed adenocarcinoma, in situ, of the uterus at age 28
years. The other primary cancers were basal cell carci-
noma, at age 23 years; hydatidiform mole, at age 27
years; and astrocytoma of the spinal cord, at age 6 years.
Mutation Analysis
One hundred ninety-one women were screened for
germline mutations in the entire coding region of
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Table 2
Results of Mutation Analysis
NO. OF CASES ANALYZED/NO. OF MUTATIONS
(95% CI)
GENE INVASIVE BORDERLINE
BRCA1 109/0 (0%–4%) 77/0 (0%–5%)
BRCA2 98/0 (0%–4%) 74/0 (0%–6%)
hMLH1 100/2 (1%–8%) 64/0 (0%–6%)
hMSH2 100/0 (0%–4%) 64/0 (0%–6%)
NOTE.—There were five index cases analyzed for mutations in all
of the genes but in which details on whether the tumors were borderline
or invasive were unknown. In the computation of the 95% CIs, we
allowed for a detection sensitivity of 70% for BRCA1 mutations. For
the calculation of the confidence limits for BRCA2 mutations, we
assumed that 73% of mutations in patients with ovarian cancer occur
in the ovarian cancer–cluster region of BRCA2 and that the PTT has
an 87% sensitivity (Hogervorst et al. 1995; Takahashi et al. 1996;
Tavtigian et al. 1996; Gayther et al. 1997; Hakansson et al. 1997;
Breast Cancer Information Core Data Base). In the computation of
the confidence limits for the SSCP/HA analysis of the hMLH1 and
hMSH2 genes, we assumed a sensitivity of 75%, which is the lowest
reported sensitivity of the technique (Orita et al. 1989a, 1989b;Condie
et al. 1993; Sheffield et al. 1993).
Table 3
Histological Diagnosis in 198 Living Women with Epithelial
Ovarian Cancer Diagnosed at Age !30 Years, with Number of Each
Subtype Analyzed for BRCA1 Mutations
NO. OF TUMORS/NO. OF TUMORS
ANALYZED
TUMOR HISTOLOGY Invasive Borderline
Serous 32/30 35/31
Mucinous 67/64 46/43
Endometrioid 4/4 2/2
Adenocarcinoma 11/11 1/1
Total 114/109 84/77
BRCA1; 177 women, for germline mutations in
BRCA2 nucleotides 3035–6629; and 169 women, for
germline mutations in MLH1 and MSH2. The age
range of these women was 13–30 years, with a median
of 25 years. The results are shown in table 2. No
mutations were detected in BRCA1, BRCA2, or
MSH2 genes, although the expected neutral variants
were detected. Two patients had probable mutations
in the hMLH1 gene. One patient had a Lys618Thr
change in hMLH1, which has previously been re-
ported as a mutation (Han et al. 1995). She presented
with a mucinous adenocarcinoma of the ovary at age
27 years; among 27 first- and second-degree relatives,
the only reported cancer was an unknown primary
cancer seen in her paternal grandmother at age 71
years. The second woman also had a Lys618Thr
change and, in addition, had an Asp304His variant
in exon 11 of hMLH1. We could not determine
whether this was on the same allele or on the opposite
allele as the Lys618Thr change. This woman had en-
dometrioid adenocarcinoma of the ovary diagnosed
at age 25 years, and, 8 mo later, transitional-cell can-
cer of her bladder developed—a pattern that is con-
sistent with the tissues known to be affected in fam-
ilies with HNPCC. No details of her family history
were received. The Asp304His variant has not pre-
viously been reported. Both of the aforementioned
changes affect residues conserved between man and
rat; both changes are nonconservative and were not
seen in 190 chromosomes screened from the general
population.
Pathology, Stage, and Residual Disease
There were substantial differences in pathology be-
tween the women who were still alive at the time of
the study (median time from diagnosis 7 years) and
those who had died (tables 3 and 4). The group who
had died had a significantly higher proportion of in-
vasive adenocarcinomas of the ovary (20% vs. 6%,
odds ratio [OR] 3.54, 95% confidence interval [CI]
1.6–7.7; , ) and other rare invasive2x = 11.7 P ! .001
histological subtypes (23% vs. 0%, , ),2x = 46 P ! .001
which most likely reflects a subgroup of tumors that
have a worse prognosis. There were no significant dif-
ferences, in the proportions of invasive serous, mucin-
ous, and endometrioid tumors, between the living and
dead groups, but the surviving group differed from the
group who had died of their disease, with regard to
the proportion with borderline tumors (41% vs. 1%,
, ), with stage 1 disease (76% vs. 24%,2x = 52 P ! .001
, ), and with residual disease !1 cm2x = 76.2 P ! .001
after the initial operation (89% vs. 31%, ,2x = 76.2
).P ! .001
Discussion
The most striking result is the failure to detect any
germline mutations (a) in BRCA1 in 101 women, and
(b) in a limited analysis of the ovarian cancer–cluster
region of BRCA2 in 98 women with invasive ovarian
cancer diagnosed at age !30 years; or (c) in either
BRCA1 or BRCA2 in 170 women with borderline tu-
mors. This result contrasts both with the experience
in early-onset breast cancer (Fitzgerald et al. 1996;
Langston et al. 1996; Krainer et al. 1997) and with
the predictions, from epidemiological studies, that
6%–18% of ovarian cancers diagnosed at age !30
years would be attributable to mutations in BRCA1
(Ford and Easton 1995; Whittemore et al. 1997). Al-
though the evidence for a higher familial relative risk
at younger ages is much weaker for ovarian cancer
than for breast cancer, the frequency of BRCA1 mu-
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Table 4
Histological Diagnosis in 36 Deceased
Women with Epithelial Ovarian Cancer
Diagnosed at Age !30 Years
NO. OF TUMORS
TUMOR HISTOLOGY Invasive Borderline
Serous 23 0
Mucinous 25 1
Endometrioid 5 0
Undifferentiated 5 0
Not specified 2 0
Adenocarcinoma 20 0
Small cell 14 0
Clear cell 1 0
Total 95 1
tations that we observed in cases of invasive cancer
diagnosed at age !30 years was actually lower than
that in our previous hospital-based series of consec-
utive cases of invasive cancer diagnosed at age !70
years (median age 53 years): 0/109 vs. 12/355 (P =
)..08
This finding is consistent with the observations
from the multiple-case families collected by the Breast
Cancer Linkage Consortium (Hall et al. 1990; Narod
et al. 1991, 1995; Easton et al. 1993, 1995, 1997;
Wooster et al. 1994). Of the 277 confirmed cases of
epithelial ovarian cancer in the entire set of families
known to carry a mutation in BRCA1 or BRCA2, only
4 were diagnosed at age !30 years. Three of these
have been shown to be phenocopies, and, in one, the
BRCA-mutation status is unknown. The finding is
also consistent with unpublished data from the United
Kingdom Co-ordinating Committee on Cancer Re-
search Familial Ovarian Cancer Register, which sug-
gest that early age at diagnosis is not a feature of
familial ovarian cancer: among 202 well-documented
families with at least two confirmed diagnoses of in-
vasive epithelial ovarian cancer in first- or second-
degree relatives, only 15 (2.7%) of 556 cases of ovar-
ian cancer for which data are available were diag-
nosed at age !35 years, and only 9 (1.6%) of 556
were diagnosed at age !30 years.
There are several caveats in the interpretation of these
results. The first two relate to the mutation analysis. This
was subject to potentially serious selection bias, in that
it was performed on blood samples and, therefore, on
surviving patients. However, this may not have affected
the results: the proportion of invasive serous tumors
(which is the histological type most frequently associated
with BRCA1 mutations) did not differ between survivors
and nonsurvivors, and current data do not suggest that
the selection of survivors would have biased against
cases with BRCA mutations (Rubin et al. 1996; Brunet
et al. 1997; Johannsson et al. 1997, 1998; Stratton et
al. 1997). Second, the mutation analysis has limited sen-
sitivity, and some mutations may therefore have been
missed. This is addressed in more detail in table 2. A
third caveat is that the pattern of histological types is
markedly different between cases diagnosed at age !30
years and those diagnosed at age 30 years. Of the 111
patients with invasive cancer who were analyzed for
germline mutations, 66 (59%) had mucinous tumors,
and only 30 (28%) of 109 had serous tumors. This com-
pares with 58% invasive serous tumors in our previous
hospital-based series of invasive ovarian cancers diag-
nosed at age !70 years. In the hospital-based series, 12
of the 13 BRCA1 mutations identified occurred within
the 203 cases of invasive serous carcinoma. If the prev-
alence was similar, this would predict two mutations in
our set of 30 invasive serous tumors diagnosed at age
!30 years. This lies within the confidence limits of our
observation that there are no mutations in this set. We
therefore cannot make any firm conclusion about dif-
ferences in the prevalence of BRCA mutations in invasive
serous carcinomas in different age groups.
The possibility of bias due to selective study of sur-
viving patients might conceivably affect the family-his-
tory analysis. However, with this reservation, the scarcity
of cases of early-onset ovarian cancer in families with
breast and ovarian cancer, the lack of strong excess risks
of breast or ovarian cancer in the relatives of cases in
the current study, and the mutation data all suggest that,
in contrast to early-onset breast cancer, diagnosis of
ovarian cancer at age !30 years is not a strong indicator
of familial susceptibility to either breast or ovarian can-
cer.
If early-onset ovarian cancers are not, in general,
part of the familial breast/ovarian cancer syndrome,
do they have characteristics suggesting that at least
some of them are distinct from the generality of-
epithelial ovarian cancer? One difference, mentioned
earlier, is suggested by the pathology. The impression
of a different spectrum of pathology in early-onset
cases in the current study is confirmed by an analysis
of all cases, irrespective of survival or our ability to
trace them, in the East Anglian Cancer Registry.
Among epithelial ovarian cancers recorded in this reg-
istry during 1987–96, 20 (39%) of 51 of those di-
agnosed at age !30 years were of borderline histology,
compared with 121 (8%) of 1,466 of those in women
of age 30–70 years at diagnosis ( ). Among theP ! .001
invasive cancers, mucinous histology was more fre-
quent in cases diagnosed at age !30 years, occurring
in 15 (48%) of 31, compared with 214 (16%) of
1,345 cases of invasive cancer diagnosed at age 30–70
years ( ).P ! .001
Another possible clue to differences might come
from the finding of distinct patterns of familial ag-
gregation in early cases. In our series, we detected a
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number of familial associations, the statistical signif-
icance of which is weakened by the large number of
comparisons made. Apart from the expected slightly
increased familial relative risk of ovarian cancer, the
most striking finding was an excess risk of both non-
Hodgkin lymphoma and multiple myeloma. Each of
these associations involved only a very small number
of cases and was not consistent between first- and
second-degree relatives, which suggests that, until fur-
ther confirmation is obtained, they should be treated
with caution. We found two individuals with germline
mutations in hMLH1, a finding that is consistent with
the known involvement of some cases of ovarian can-
cer in the HNPCC syndrome; however, the upper con-
fidence limits for the prevalence of mutations in
hMSH2 and hMLH1 combined was only 12%.
In sum, our data suggest that ovarian cancers diag-
nosed at age !30 years differ from those diagnosed at
later ages, in that they contain a higher proportion of
both borderline cases and mucinous histology among
invasive cases. In the great majority of cases, there is no
evidence of strong hereditary predisposition. One of the
motivations to perform this study was a series of clinical
referrals of sisters of young women who had had in-
vasive ovarian cancer diagnosed in their 20s, with the
question of risk to the sisters and the advisability of
prophylactic oophorectomy. The conclusion that we
draw from our data is that, in the absence of a suggestive
family history, the risks to such young women are prob-
ably not greatly increased and that drastic measures,
such as oophorectomy, are unnecessary.
Acknowledgments
We thank the cancer registries throughout the United
Kingdom, the ethics committees who approved this study,
the Family Health Services Authorities, the Office for Na-
tional Statistics, and the clinicians and patients who con-
tributed to this study. The study was supported by a pro-
gram grant (to B.A.J.P.) and fellowship (to J.F.S.) from
WellBeing, by The Cancer Research Campaign (support to
D.T., D.E., and B.A.J.P.), and by The Imperial Cancer Re-
search Fund (support to D.T.B.). B.A.J.P. is a Gibb Fellow
of the Cancer Research Campaign.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Breast Cancer Information Core Data Base, http://www.nhgri
.nih.gov/Intramural_research/Lab_transfer/Bic/
International Agency for Research on Cancer, World Health
Organization, http://www-DEP.IARC.FR/dataava/globocan
/globoJava.html
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim (for BRCA1 [MIM 113705] and
BRCA2 [MIM 600185])
References
Borresen AL, Lothe RA, Meling GI, Lystad S, Morrison P,
Lipford J, Kane MF, et al (1995) Somatic mutations in the
hMSH2 gene in microsatellite unstable colorectal carcino-
mas. Hum Mol Genet 4:2065–2072
Brunet JS, Narod SA, Tonin P, Foulkes WD (1997) BRCA1
mutations and survival in women with ovarian cancer. N
Engl J Med 336:1256
Coleman M, Douglas A, Hermon C, Peto J (1989) PYRS—a
fortran program for cohort study analysis. IARC internal
report no. 891006. International Agency for Research on
Cancer, Lyon, France
Condie A, Eeles R, Borresen A-L, Coles C, Cooper C, Prosser
J (1993) Detection of point mutations in the p53 gene: com-
parison of single-strand conformation polymorphism, de-
naturing gradient gel electrophoresis, and hydroxylamine
and osmium tetroxide techniques. Hum Mutat 2:58–66
Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic
linkage analysis in familial breast and ovarian cancer: results
from 214 families. The Breast Cancer Linkage Consortium.
Am J Hum Genet 52:678–701
Easton DF, Ford D, Bishop DT (1995) Breast and ovarian
cancer incidence in BRCA1-mutation carriers. The Breast
Cancer Linkage Consortium. Am J Hum Genet 56:265–271
Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA,
McManus R, et al (1997) Cancer risks in two large breast
cancer families linked to BRCA2 on chromosome 13q12-
13. Am J Hum Genet 61:120–128
Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O’Neil
E, Unsal H, Silva-Arrieto S, et al (1996) Germ-line BRCA1
mutations in Jewish and non-Jewish women with early-onset
breast cancer. N Engl J Med 334:143–149
Ford D, Easton DF (1995) The genetics of breast and ovarian
cancer. Br J Cancer 72:805–812
Ford D, Easton DF, Peto J (1995) Estimates of the gene fre-
quency of BRCA1 and its contribution to breast and ovarian
cancer incidence. Am J Hum Genet 57:1457–1462
Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott
IV, Jacobs I, et al (1996) Somatic and germline mutations
of the BRCA2 gene in sporadic ovarian cancer. Cancer Res
56:3622–3625
Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B,
Casey G, Ponder BA, et al (1997) Mutation analysis of
BRCA1 and BRCA2 in a male breast cancer population. Am
J Hum Genet 60:313–319
Gayther SA, Harrington P, Russell P, Kharkevich G, Garkav-
tseva RF, Ponder BA (1996) Rapid detection of regionally
clustered germ-line BRCA1 mutations by multiplex heter-
oduplex analysis. UKCCCR Familial Ovarian Cancer Study
Group Am J Hum Genet 58:451–456
Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder
BA, Stratton MR, et al (1997) Variation of risks of breast
and ovarian cancer associated with different germline mu-
tations of the BRCA2 gene. Nat Genet 15:103–105
Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington
PA, Chiano M, Seal S, et al (1995) Germline mutations of
1732 Am. J. Hum. Genet. 65:1725–1732, 1999
the BRCA1 gene in breast and ovarian cancer families pro-
vide evidence for a genotype-phenotype correlation. Nat Ge-
net 11:428–433
Glavac D, Dean M (1993) Optimization of the single-strand
conformation polymorphism (SSCP) technique for detection
of point mutations. Hum Mutat 2:404–414
——— (1995) Applications of heteroduplex analysis for mu-
tation detection in disease genes. Hum Mutat 6:281–287
Hakansson S, Johannsson O, Johansson U, Sellberg G, Lo-
man N, Gerdes AM, Holmberg E, et al (1997) Moderate
frequency of BRCA1 and BRCA2 germ-line mutations in
Scandinavian familial breast cancer. Am J Hum Genet 60:
1068–1078
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA,
Huey B, King M-C (1990) Linkage of early-onset familial
breast cancer to chromosome 17q21. Science 250:1684–
1689
Han HJ, Maruyama M, Baba S, Park JG, Nakamura Y (1995)
Genomic structure of human mismatch repair gene,
hMLH1, and its mutation analysis in patients with hered-
itary non-polyposis colorectal cancer (HNPCC). Hum Mol
Genet 4:237–242
Han HJ, Yuan Y, Ku JL, Oh JH, Won YJ, Kang KJ, Kim KY,
et al (1996) Germline mutations of hMLH1 and hMSH2
genes in Korean hereditary nonpolyposis colorectal cancer.
J Natl Cancer Inst 88:1317–1319
Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk
JC, Olmer R, Bakker B, et al (1995) Rapid detection of
BRCA1 mutations by the protein truncation test. Nat Genet
10:208–212
Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir
RB, Egilsson V, Olsson H (1997) Tumour biological features
of BRCA1-induced breast and ovarian cancer. Eur J Cancer
33:362–371
Johannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival
of BRCA1 breast and ovarian cancer patients: a population-
based study from southern Sweden. J Clin Oncol 16:397–
404
Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ish-
ioka C, Kanamaru R, MacDonald DJ, et al (1997) Differ-
ential contribution of BRCA1 and BRCA2 to early-onset
breast cancer. N Engl J Med 336:1416–1421
Langston AA, Malone KE, Thompson JD, Daling JR, Ostran-
der EA (1996) BRCA1 mutations in a population-based
sample of young women with breast cancer. N Engl J Med
334:137–142
Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham
JM, French AJ, Halling KC, et al (1996) Microsatellite in-
stability and mutation analysis of hMSH2 and hMLH1 in
patients with sporadic, familial and hereditary colorectal
cancer. Hum Mol Genet 5:1245–1252
Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch
J, Lenoir GM (1991) Familial breast-ovarian cancer locus
on chromosome 17q12-q23. Lancet 338:82–83
Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT,
Smith SA, Ponder BAJ, et al (1995) An evaluation of genetic
heterogeneity in 145 breast-ovarian cancer families. Am J
Hum Genet 56:254–264
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T
(1989a) Detection of polymorphisms of human DNA by gel
electrophoresis as single strand conformation polymor-
phisms. Proc Natl Acad Sci USA 86:2766–2770
Orita M, Suzuki Y, Sekiya T, Hayashi K (1989b) Rapid and
sensitive detection of point mutations and DNA polymor-
phisms using the polymerase chain reaction. Genomics 5:
874–879
Rossetti S, Corra S, Biasi MO, Turco AA, Pignatti P (1995)
Comparison of heteroduplex and single-strand conforma-
tion analyses, followed by ethidium fluorescence visualiza-
tion, for the detection of mutations in four human genes.
Mol Cell Probes 9:195–200
Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan
MA, LiVolsi VA, Berchuck A, et al (1996) Clinical and path-
ological features of ovarian cancer in women with germ-line
mutations of BRCA1. N Engl J Med 335:1413–1416
Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM
(1993) The sensitivity of single-strand conformation poly-
morphism analysis for the detection of single base substi-
tutions. Genomics 16:325–332
Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake
P, Easton D, et al (1997) Contribution of BRCA1 mutations
to ovarian cancer. N Engl J Med 336:1125–1130
Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC,
Couch FJ, Weber BL, et al (1996) Mutations of the BRCA2
gene in ovarian carcinomas. Cancer Res 56:2738–2741
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens
D, Neuhausen S, Merajver S, et al (1996) The complete
BRCA2 gene and mutations in chromosome 13q-linked kin-
dreds. Nat Genet 12:333–337
Whittemore AS, Gong G, Itnyre J (1997) Prevalence and con-
tribution of BRCA1 mutations in breast cancer and ovarian
cancer: results from the three U.S. population-based case-
control studies of ovarian cancer. Am J Hum Genet 60:
496–504
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Col-
lins N, Nguyen K, et al (1994) Localization of a breast cancer
susceptibility gene, BRCA2, to chromosome 13q12-13. Sci-
ence 265:2088–2090
